MoneyWorks4Me

Zydus Lifesciences reports 36% decline in Q1 consolidated net profit

11 Aug 2026 Evaluate

Zydus Lifesciences has reported its results for the first quarter ended June 30, 2026 (Q1FY27).

The company has reported an 11.72% decline in its net profit at Rs 339.60 crore for the quarter ended June 30, 2026, as compared to Rs 384.70 crore for the same quarter in the previous year. However, total income increased by 9.12% to Rs 2,995.90 crore for Q1FY27 as compared to Rs 2,745.40 crore for the corresponding quarter of the previous year.

On a consolidated basis, the company has reported a 35.93% decline in its net profit at Rs 939.80 crore for Q1FY27, as compared to Rs 1,466.80 crore for the same quarter in the previous year. However, total income increased by 20.72% to Rs 8,123.10 crore for Q1FY27 as compared to Rs 6,728.60 crore for the corresponding quarter of the previous year.

Zydus Lifesciences Share Price

1180.00 59.30 (5.29%)
11-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1940.00
Dr. Reddys Labs. 1205.00
Cipla 1462.00
Lupin 2278.00
Zydus Lifesciences 1180.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: